4 results
The study objective is to assess the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) compared to the Resolute IntegrityTM Drug-Eluting Stent in patients with single, de novo coronary artery lesions.
Primary: To demonstrate non-inferiority of RELVAR 100/25 once-daily to SERETIDE 250/50 twice-daily in adult and adolescent subjects 12 years of age and older with persistent asthma,adequately controlled on twice-daily ICS/LABA. Secondary: Adverse…
Efficacy and safety during 24 treatment weeks.
The study objective is to assess the safety and efficacy of the Svelte DES-IDS and the Svelte DES-RX compared to a commercially available Xience or Promus Drug-Eluting Stent in subjects with up to three de novo coronary artery lesions in up to two…